Insider Selling: Moderna, Inc. (NASDAQ:MRNA) Director Sells $1,663,800.00 in Stock

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the completion of the transaction, the director now owns 2,026,931 shares in the company, valued at $224,827,186.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, April 24th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.32, for a total transaction of $1,624,800.00.
• On Wednesday, April 17th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $103.38, for a total transaction of $1,550,700.00.
• On Wednesday, April 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $107.12, for a total transaction of $1,606,800.00.
• On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $101.68, for a total transaction of $1,525,200.00.
• On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $109.06, for a total transaction of $1,635,900.00.
• On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $102.39, for a total transaction of $1,535,850.00.
• On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $108.54, for a total transaction of $1,628,100.00.

Moderna Stock Down 0.5 %

Shares of NASDAQ MRNA opened at $125.00 on Monday. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $142.79. The company has a market capitalization of $47.86 billion, a PE ratio of -7.98 and a beta of 1.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.36. The firm’s 50-day moving average is $105.05 and its two-hundred day moving average is $94.48.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. During the same quarter in the prior year, the firm earned $0.19 earnings per share. The company’s revenue for the quarter was down 91.0% compared to the same quarter last year. Equities analysts anticipate that Moderna, Inc. will post -7.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Moderna

Several institutional investors and hedge funds have recently modified their holdings of MRNA. Simplicity Solutions LLC lifted its stake in shares of Moderna by 12.7% during the third quarter. Simplicity Solutions LLC now owns 4,411 shares of the company’s stock valued at $456,000 after buying an additional 497 shares during the period. Xponance Inc. lifted its stake in shares of Moderna by 2.3% during the third quarter. Xponance Inc. now owns 39,920 shares of the company’s stock valued at $4,123,000 after buying an additional 910 shares during the period. Raymond James & Associates lifted its stake in shares of Moderna by 20.3% during the third quarter. Raymond James & Associates now owns 186,342 shares of the company’s stock valued at $19,247,000 after buying an additional 31,423 shares during the period. Stratos Wealth Advisors LLC purchased a new position in shares of Moderna during the third quarter valued at approximately $312,000. Finally, Woodmont Investment Counsel LLC increased its position in Moderna by 11.5% during the third quarter. Woodmont Investment Counsel LLC now owns 9,300 shares of the company’s stock worth $961,000 after purchasing an additional 960 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on MRNA shares. William Blair reiterated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Oppenheimer boosted their price target on shares of Moderna from $142.00 to $163.00 and gave the stock an “outperform” rating in a research note on Friday. Royal Bank of Canada boosted their price target on shares of Moderna from $125.00 to $135.00 and gave the stock an “outperform” rating in a research note on Friday. HSBC reiterated a “reduce” rating and set a $86.00 price target (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Finally, Canaccord Genuity Group boosted their price objective on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $129.55.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.